Using epigenetic compounds to help repair dental bone loss
Epigenetic Compounds Stimulating Dental Bone Repair
This study is looking at a new way to help older adults with periodontitis, a gum disease that can cause bone loss around teeth, by using special treatments that might help grow new bone and repair the damage.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cayman Chemical Company, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11067062 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for patients suffering from periodontitis, a condition that leads to the loss of alveolar bone around teeth. By targeting specific epigenetic enzymes, the study aims to stimulate the growth of bone-forming cells, potentially reversing the damage caused by chronic inflammation. The approach involves using small molecules that can be incorporated into various delivery methods, making it a cost-effective and versatile option for patients. The research is particularly relevant for older adults who are more susceptible to bone loss in the mouth.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing alveolar bone loss due to periodontitis, particularly older adults.
Not a fit: Patients who do not have periodontitis or significant alveolar bone loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and affordable treatment option for patients with dental bone loss, improving their oral health and quality of life.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting epigenetic mechanisms to promote bone regeneration.
Where this research is happening
Ann Arbor, United States
- Cayman Chemical Company, INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Kennedy, Paul Douglas — Cayman Chemical Company, INC.
- Study coordinator: Kennedy, Paul Douglas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.